ASH 2018 | Updated pivotal ELIANA study results for CAR T-cell product tisagenlecleucel in ALL
Stephan Grupp
• 4 Dec 2018
The FDA approved the CD19-directed CAR T-cell product tisagenlecleucel in 2017 for the treatment of acute lymphoblastic leukemia (ALL), based on results from the Phase II pivotal ELIANA trial (NCT02435849). Here, Stephan Grupp, MD, PhD, of the Children’s Hospital of Philadelphia, Philadelphia, PA, presents an update of ELIANA with additional patients and a further 11 months follow-up since the previous report, from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
